[go: up one dir, main page]

TW200833359A - Elution-improved pharmaceutical preparation - Google Patents

Elution-improved pharmaceutical preparation

Info

Publication number
TW200833359A
TW200833359A TW096149681A TW96149681A TW200833359A TW 200833359 A TW200833359 A TW 200833359A TW 096149681 A TW096149681 A TW 096149681A TW 96149681 A TW96149681 A TW 96149681A TW 200833359 A TW200833359 A TW 200833359A
Authority
TW
Taiwan
Prior art keywords
elution
pharmaceutical preparation
improved pharmaceutical
pharmaceutical composition
olmesartan medoxomil
Prior art date
Application number
TW096149681A
Other languages
Chinese (zh)
Other versions
TWI414310B (en
Inventor
Shuichi Yada
Mitsuru Kanno
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of TW200833359A publication Critical patent/TW200833359A/en
Application granted granted Critical
Publication of TWI414310B publication Critical patent/TWI414310B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides the dissolution improved pharmaceutical composition comprising olmesartan medoxomil and azelnidipine. The said pharmaceutical composition comprises (A) olmesartan medoxomil, (B) azelnidipin, and (c) polyvinylalcohol or vinyl alcohol-based copolymers.
TW096149681A 2006-12-26 2007-12-24 Elution-improved pharmaceutical preparation TWI414310B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006349473 2006-12-26

Publications (2)

Publication Number Publication Date
TW200833359A true TW200833359A (en) 2008-08-16
TWI414310B TWI414310B (en) 2013-11-11

Family

ID=39562516

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096149681A TWI414310B (en) 2006-12-26 2007-12-24 Elution-improved pharmaceutical preparation

Country Status (4)

Country Link
JP (1) JP5241511B2 (en)
KR (1) KR20090094287A (en)
TW (1) TWI414310B (en)
WO (1) WO2008078727A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170912A (en) * 2008-09-30 2011-08-31 大洋药品工业株式会社 Compression-molded preparation and method for producing the same
KR101148884B1 (en) * 2010-02-01 2012-05-29 동성제약주식회사 Composition for prevention or treatment hypertension comprising olmesartan medoxomil with an increased dissolution rate
JP5421945B2 (en) * 2010-03-10 2014-02-19 大日本住友製薬株式会社 Pharmaceutical composition containing irbesartan and amlodipine or a salt thereof
JP6227352B2 (en) * 2012-09-27 2017-11-08 株式会社三和化学研究所 Solid preparation containing anagliptin or a salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
CN1762354B (en) * 2004-10-18 2010-07-28 上海药明康德新药开发有限公司 A stable pharmaceutical composition containing a calcium blocker
KR101318032B1 (en) * 2005-05-20 2013-10-14 다이이찌 산쿄 가부시키가이샤 Film coated preparation
TWI367756B (en) * 2005-05-20 2012-07-11 Sankyo Co A film-coated drug product comprising dextrose
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker

Also Published As

Publication number Publication date
JPWO2008078727A1 (en) 2010-04-30
TWI414310B (en) 2013-11-11
WO2008078727A1 (en) 2008-07-03
JP5241511B2 (en) 2013-07-17
KR20090094287A (en) 2009-09-04

Similar Documents

Publication Publication Date Title
SG169353A1 (en) Tamper resistant dosage forms
CL2007002640A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002642A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
TW200740459A (en) Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
WO2007076260A3 (en) Farnesoid x receptor agonists
WO2008127364A3 (en) Antiviral compounds and use thereof
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
CL2008000751A1 (en) COMPOUNDS DERIVED FROM CICLOPROP [D] INDOLO [2,1-A] [2] BENZACEPINE SUBSTITUTED WITH HETEROCICLES; PHARMACEUTICAL COMPOSITION; AND USE IN HEPATITIS C INFECTION TREATMENT.
MX2008001652A (en) Polyammonium/polysiloxane copolymers.
CL2007002376A1 (en) COMPOUNDS DERIVED FROM REPLACED PIRROL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN BACTERIAL DISEASES.
TW200731991A (en) Lipophilic di(anticancer drug) compounds, compositions and related methods
WO2009152167A3 (en) Delivery of therapeutics
TW200833359A (en) Elution-improved pharmaceutical preparation
IL197766A (en) Use of a glycopeptide antibiotic in the preparation of a medicament for the prevention of b. anthracis infection
WO2008093247A3 (en) Medicament for the treatment of endometriosis
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
WO2007078271A3 (en) Lansoprazole orally disintegrating tablets
EP2574340A3 (en) Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
MX2008010233A (en) Modified release composition comprising doxofylline.
EA200901387A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DESLORATADINE
WO2007075980A3 (en) Lansoprazole orally disintegrating tablets
FR2904415B3 (en) DOSAGE SPOON.
BRPI0919168A2 (en) mutant pestivirus and vaccine.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees